Zepbound

News

Lilly Kenosha County - Expansion Rendering

Lilly invests another $3bn in its manufacturing network

Lilly will spend $3 billion on a recently acquired Wisconsin plant for injectable medicines, including diabetes and obesity drugs.

News

Zepbound tops Wegovy in first head-to-head weight-loss trial

Eli Lilly is playing catch-up to Novo Nordisk in the fast-growing obesity therapy sector but has new data that could tip the balance in its favour.

News

Wegovy romps ahead after key rival sees slowdown

Novo Nordisk's sales of blockbuster obesity drug Wegovy grew by a massive 79% in the third quarter, in a relief to investors after disappointing results three months ago.

News

FDA rethinking block on compounding of Lilly's obesity drug

The FDA has said it has agreed to reconsider its decision to prevent compounding pharmacies from producing and selling versions of Eli Lilly's diabetes and obesity drug tirzepatide.

News

Mounjaro and Zepbound shortages over, declares FDA

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in

News

Lilly launches single-dose Zepbound to ease self-pay access

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford

Lilly invests another $3bn in its manufacturing network

Zepbound tops Wegovy in first head-to-head weight-loss trial

Wegovy romps ahead after key rival sees slowdown

FDA rethinking block on compounding of Lilly's obesity drug

Mounjaro and Zepbound shortages over, declares FDA

Lilly launches single-dose Zepbound to ease self-pay access

NHS use of digital cardiac rehab tools endorsed

How to meet your physicians where they are online

Zepbound

Editor's Picks